Ignite Creation Date:
2024-05-06 @ 9:23 AM
Last Modification Date:
2024-10-26 @ 12:14 PM
Study NCT ID:
NCT02974725
Status:
TERMINATED
Last Update Posted:
2024-05-17
First Post:
2016-11-23
Brief Title:
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Melanoma |
| Non-Small Cell Lung Cancer |
Keywords:
| Name | View |
|---|---|
| squamous cell lung carcinoma | View |
| NSCLC | View |
| Melanoma | View |
| NRAS | View |
| KRAS | View |
| BRAF | View |
| LXH254 | View |
| LTT462 | View |
| Trametinib | View |
| Ribocliclib | View |
| Non-small cell lung carcinoma NSCLC | View |
| treatment of lung cancer after first metastasis | View |
| lung cancer | View |
| lung adenocarcinoma | View |
| Large-cell lung carcinoma | View |
| Non small cell lung carcinoma | View |
| Non small cell lung cancer | View |
| Large cell lung carcinoma | View |
| Large cell lung cancer | View |